PE20090107A1 - Anticuerpos de union al antigeno igf-1r - Google Patents
Anticuerpos de union al antigeno igf-1rInfo
- Publication number
- PE20090107A1 PE20090107A1 PE2008000303A PE2008000303A PE20090107A1 PE 20090107 A1 PE20090107 A1 PE 20090107A1 PE 2008000303 A PE2008000303 A PE 2008000303A PE 2008000303 A PE2008000303 A PE 2008000303A PE 20090107 A1 PE20090107 A1 PE 20090107A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- fab
- breast
- fragment
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
REFERIDA A UN ANTICUERPO, HUMANIZADO O QUIMERICO, O FRAGMENTO DE UNION AL ANTIGENO IGF-1R (RECEPTOR DEL FACTOR DE CRECIMIENTO SIMILAR A INSULINA HUMANO) QUE COMPRENDE LA CDR H3 DE LA SEC ID Nº1 O UNA VARIANTE DE LA MISMA CON UNA O DOS SUSTITUCIONES DE AMINOACIDOS EN LA CDRH3 Y QUE COMPRENDE ADEMAS UNA O MAS DE LAS SECUENCIAS CDRH2: SEC ID Nº2 O CDRH1: SEC ID Nº3, CDRL1: SEC ID Nº4, CDRL2: SEC ID Nº7 Y CDRL3: SEC ID Nº6, DONDE EL ANTICUERPO ES UN ANTICUERPO IgG1 Y EL FRAGMENTO ES UN Fab, Fab', F(ab')2, Fv, DIACUERPO, TRIACUERPO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA CELULA HUESPED TRANSFORMADA, TRANSFECTADA O TRANSDUCIDA. DICHO ANTICUERPO TIENE FUNCIONES EFECTORAS O DE ACTIVACION DE COMPLEMENTO Y/O ADCC (CITOTOXICIDAD CELULAR DEPENDIENTE DEL ANTICUERPO) REDUCIDA Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, CANCERES TALES COMO CANCER DE MAMA, PROSTATA, PULMON, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0702888.9A GB0702888D0 (en) | 2007-02-14 | 2007-02-14 | Novel Antibodies |
| US95321007P | 2007-08-01 | 2007-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090107A1 true PE20090107A1 (es) | 2009-03-20 |
Family
ID=42025950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000303A PE20090107A1 (es) | 2007-02-14 | 2008-02-12 | Anticuerpos de union al antigeno igf-1r |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2010518140A (es) |
| KR (1) | KR20090114449A (es) |
| EA (1) | EA200900991A1 (es) |
| MX (1) | MX2009008754A (es) |
| PE (1) | PE20090107A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3027824A1 (en) * | 2010-02-23 | 2011-09-01 | Sanofi | Anti-alpha2 integrin antibodies and their uses |
| UY33578A (es) | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
| BR112014014418A2 (pt) * | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | proteínas de fusão fc de receptor igf solúvel e usos das mesmas |
| CN108473549A (zh) * | 2015-10-23 | 2018-08-31 | 阿珀吉科吉尼科斯股份公司 | 单链gitr受体激动剂蛋白 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305995B (en) * | 2001-01-05 | 2004-08-04 | Pfizer | Antibodies to insulin-like growth factor I receptor. |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| ES2527871T3 (es) * | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
| WO2005058967A2 (en) * | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| WO2007000328A1 (en) * | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
-
2008
- 2008-02-12 JP JP2009549402A patent/JP2010518140A/ja active Pending
- 2008-02-12 PE PE2008000303A patent/PE20090107A1/es not_active Application Discontinuation
- 2008-02-12 MX MX2009008754A patent/MX2009008754A/es unknown
- 2008-02-12 EA EA200900991A patent/EA200900991A1/ru unknown
- 2008-02-12 KR KR1020097018932A patent/KR20090114449A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009008754A (es) | 2009-11-02 |
| EA200900991A1 (ru) | 2010-02-26 |
| JP2010518140A (ja) | 2010-05-27 |
| KR20090114449A (ko) | 2009-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| JP2020500538A5 (es) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2018534933A5 (es) | ||
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20090368A1 (es) | Anticuerpos anti-igf | |
| RU2008101772A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| AR061115A1 (es) | Anticuerpos anti- interleuquina 18 (il-18) | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| RU2022111211A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| PE20091342A1 (es) | Inmunoglobulinas | |
| MX2009003838A (es) | Anticuerpos anti-cd20 y metodos de uso. | |
| AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |